Friday 6 November 2026 Export CPHI’s income statement to Excel — free account

China Pharma Holdings, Inc.

CPHI Healthcare Drug Manufacturers Specialty & Generic

China Pharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, down 8.49% from fiscal 2024.

Revenue: −7.56%
EPS: +75.0%
Free cash flow: −113.6%
Total debt: −2.92%

Quarter to June 2026, against a year earlier

0.56 0.03 +5.66%

Follow CPHI

Alert me

Market cap: $22.8M
P/E: 0.0×
Fwd P/E: −1.3×
Dividend yield: —
F-score: 5/9
Altman Z: −2.16
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.45%

Capital & Financial Ratios $m

Size

Market Cap 22.81

Revenue ttm 3.91

Net income ttm (4.47)

Free cash flow ttm (0.14)

Net debt Q 1.65

Valuation

P/E 0.00

Forward P/E (1.27)

Price / sales 5.49

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.59

Financial health

Current ratio Q 0.26

Debt / equity Q 0.05

Interest coverage Q (54.23)

Growth

Revenue growth Q −7.56%

Operating income growth Q −119.57%

EPS, this year —

EPS, next year A —

Revenue, next year A −15.99%

EPS, past 5 yrs —

EPS, next 5 yrs A +10.00%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 96.48%

10-year low 10-year high

P/B against its own 10 years 56.47%

10-year low 10-year high

EV/Sales against its own 10 years 96.48%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	1	0	0
Receivables	1	0	0	0
Inventory	4	2	2	1
Other	0	0	0	0
	6	3	2	2

	2023	2024	2025	Q'26
Payables	1	0	1	1
ST’ Debt	1	1	2	2
Other	0	0	0	0
	7	5	7	8

Compound Annual Growth %

	10y	5y	3y
Sales	(14.71%)	(17.53%)	(20.03%)
Cash Flow	(26.78%)	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(10.97%)	23.22%	74.36%

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.04)	(0.04)	—	—	—
’25	(0.24)	(0.16)	(0.17)	(0.18)	(0.74)
’24	(0.70)	(0.90)	(0.65)	(0.50)	(2.70)
’23	(3.00)	(3.00)	(3.00)	(1.62)	(9.10)
’22	(10.00)	(10.00)	(7.90)	(9.87)	(38.00)
’21	(10.00)	(10.00)	(10.00)	(10.00)	(35.00)
’20	(7.58)	0.15	(10.00)	(15.00)	(35.00)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	1	1	1	4
’24	1	1	1	1	5
’23	2	1	2	2	7
’22	2	2	2	3	8
’21	2	2	2	3	10
’20	2	4	2	3	11

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	0
’24	(1)	0	0	0	0
’23	(1)	0	1	0	(1)
’22	(1)	0	0	1	0
’21	0	1	0	0	0
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	0
’24	(1)	0	0	0	(1)
’23	(1)	0	1	0	(1)
’22	(1)	(1)	0	1	(1)
’21	0	1	(1)	0	(1)
’20	(1)	0	0	1	(1)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	16	13	12	11	11	10	8	7	5	4	4		(13.7%)	—	—	—	—
	Gross margin, %	20.67	18.68	16.02	13.57	17.97	3.62	(6.09)	(4.01)	(43.84)	(3.18)	11.76		(23.8) pt	Powerpack China Pharma Holdings, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(9)	(19)	(11)	(21)	(3)	(3)	(4)	(3)	(5)	(3)	(4)		(10.8%)
	EBT margin, %	(56.99)	(144.98)	(88.07)	(189.51)	(26.38)	(35.26)	(49.02)	(43.91)	(104.58)	(76.92)	(114.33)		(19.9) pt
	Net income	(9)	(19)	(11)	(21)	(3)	(3)	(4)	(3)	(5)	(3)	(4)		(11.1%)
Per share, $
Per share, $	Revenue	178.56	151.52	141.41	125.27	124.62	104.46	77.11	20.72	2.59	0.97	0.10		(44.0%)
	Earnings	(105.00)	(220.00)	(125.00)	(240.00)	(35.00)	(35.00)	(38.00)	(9.10)	(2.70)	(0.74)	(0.43)		(42.3%)
	Cash flow	33.21	9.65	21.58	6.98	(0.49)	(2.71)	(3.90)	(2.07)	(0.23)	0.03	0.00		(53.4%)
	Capex	(2.22)	(1.57)	(0.59)	(1.56)	(9.95)	(4.75)	(3.82)	(0.03)	(0.17)	(0.03)	0.00		(37.6%)
	Free cash flow	30.99	8.08	21.00	5.42	(10.43)	(7.45)	(7.72)	(2.10)	(0.40)	0.00	0.00		(64.8%)
	Book value	675.56	493.94	346.32	105.94	91.79	65.20	40.82	22.03	4.44	5.30	0.89		(41.6%)
	Shares, m	0	0	0	0	0	0	0	0	2	4	19		+54.2%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	0.71	0.57	0.91	0.95	1.79	2.31	0.56	0.28	0.90	1.25	5.49		1.0
	P/B	0.19	0.18	0.37	1.12	2.43	3.70	1.07	0.27	0.53	0.23	0.59		1.0
	EV/Sales	1.12	1.06	1.24	1.23	2.18	2.79	1.20	0.42	1.29	1.97	6.25		1.4
	EV/FCF	22.62	(11.39)	(150.30)	(9.17)	(8.33)	(11.26)	(3.54)	(1.11)	(2.49)	(184.67)	(73.47)		(36.0)
Cash, $m
Cash, $m	Operating cash flow	3	1	2	1	0	0	0	(1)	0	0	0		(28.1%)
	Capex	0	0	0	0	(1)	0	0	0	0	0	0		(3.7%)
	Free cash flow	3	1	2	0	(1)	(1)	(1)	(1)	(1)	0	0		(45.7%)
Balance, $m
Balance, $m	Working capital	7	3	(1)	(4)	(6)	(1)	(7)	(1)	(2)	(5)	(6)		n/m
	Net debt	6	6	4	3	4	5	0	1	2	2	2		(14.0%)
	Shareholders’ equity	59	43	30	9	8	6	4	7	8	23	36		(10.0%)
Returns, %
Returns, %	ROA	(10.49)	(27.84)	(20.41)	(61.24)	(13.23)	(15.53)	(19.65)	(17.98)	(30.21)	(13.89)	(15.30)		(3.4) pt
	ROIC	(7.81)	(23.58)	(19.06)	(103.64)	(13.17)	(16.79)	(47.32)	(20.46)	(30.16)	(8.31)	(7.23)		(0.5) pt
	ROE	(13.96)	(37.81)	(29.34)	(104.99)	(33.25)	(48.49)	(77.08)	(52.43)	(62.31)	(20.91)	(20.99)		(7.0) pt
People
People	Employees	385	296	252	242	248	246	244	239	231	221	—		(6.0%)
	Revenue/emp, $m	0.04	0.04	0.05	0.05	0.04	0.04	0.03	0.03	0.02	0.02	—		(8.2%)

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ZYBT Zhengye Biotechnology Holding Limited	$41.0M	—	—	—	—	−69.31% (below 0%: shrinking)	—	—	Compare
INCR InterCure Ltd.	$39.1M	6.2×	— (loss-making)	−6.53% (below 0%: shrinking)	n/m	+389.50% (above 0%: growing)	32.04%	0.00%	Compare
SCYX SCYNEXIS, Inc.	$32.8M	— (loss-making)	— (loss-making)	−8.56% (below 0%: shrinking)	n/m	−98.60% (below 0%: shrinking)	100.00%	(3,308.51%)	Compare
RMTI Rockwell Medical, Inc.	$30.6M	— (loss-making)	— (loss-making)	+10.63% (above 0%: growing)	n/m	−12.92% (below 0%: shrinking)	18.24%	(5.97%)	Compare
IXHL Incannex Healthcare Inc.	$28.5M	— (loss-making)	— (loss-making)	−92.31% (below 0%: shrinking)	n/m	+327.73% (above 0%: growing)	100.00%	0.00%	Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc.	$24.0M	— (loss-making)	—	—	n/m	+82.01% (above 0%: growing)	0.00%	0.00%	Compare
CPHI China Pharma Holdings, Inc.	$22.8M	— (loss-making)	— (loss-making)	−7.56% (below 0%: shrinking)	n/m	−113.57% (below 0%: shrinking)	8.82%	(150.99%)
TXMD TherapeuticsMD, Inc.	$19.8M	— (loss-making)	18.9×	−8.72% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+104.46% (above 0%: growing)	100.00%	(93.90%)	Compare
AYTU Aytu BioPharma, Inc.	$19.7M	— (loss-making)	— (loss-making)	+6.42% (above 0%: growing)	n/m	+57.72% (above 0%: growing)	64.63%	(4.82%)	Compare
Median of peers	$29.6M	—	—	−7.54%	—	+69.87%	64.63%	(4.82%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 14 November 2025

Ownership

Directors and executive officers, together 6.40%

Yan Yang 8.96%

Wenlong Zhan 8.16%

Kui Lai 7.96%

Jianying Cai 7.96%

Lihua Li 7.96%

Zhilin Li President, Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board 6.03%

Zhilin Li 6.03%

Tao Liu 5.97%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement